聚合内容 The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
更新时间: 53 分钟 4 秒 前

AbbVie's HUMIRA(R) (Adalimumab) Receives First and Only Health Canada Approval for Moderate to Severe Hidradenitis Suppurativa

周三, 01/06/2016 - 14:15
Hidradenitis suppurativa (HS) is a painful chronic inflammatory skin disease MONTREAL, Jan. 6, 2016 (Healthcare Sales & Marketing Network) - AbbVie, a global biopharmaceutical company, today announced that Health Canada approved HUMIRA® (adalimumab)...
Biopharmaceuticals, Regulatory
AbbVie, HUMIRA, adalimumab, hidradenitis

NextCure, Inc., New Immuno-Oncology Firm, Announces $67 Million Series A Financing

周三, 01/06/2016 - 13:54
GERMANTOWN, Md. and NEW HAVEN, Conn., Jan. 6, 2016 -- (Healthcare Sales & Marketing Network) -- NextCure, Inc., a newly formed biopharmaceutical company focused on the discovery and development of new immuno-oncology products, today announced that it has ...
Biopharmaceuticals, Oncology, Venture Capital
NextCure, immunotherapy

Vascular Dynamics’ MobiusHD(TM) System Receives CE Mark for the Treatment of Resistant Hypertension

周三, 01/06/2016 - 13:49
System offers novel approach for controlling hypertension using the body’s natural hypertension control mechanism MOUNTAIN VIEW, Calif.--(Healthcare Sales & Marketing Network)--Vascular Dynamics, Inc., a private medical device company developing novel s...
Devices, Cardiology, Regulatory
Vascular Dynamics, MobiusHD, resistant hypertension, hypertension

Origin Sciences Secures North American Distributor

周三, 01/06/2016 - 13:43
LONDON & CAMBRIDGE--(Healthcare Sales & Marketing Network)--Origin Sciences Ltd, a medical technology company developing unique sampling devices and diagnostics for the stratification of patients with gastrointestinal diseases, has secured Metabiomics as a...
Devices, Diagnostics, Distribution
Origin Sciences, Metabiomics

Vernalis Announces Corvus Pharmaceuticals, Inc. as Its Worldwide Licensee for Their Adenosine Antagonist Program

周三, 01/06/2016 - 13:36
Adenosine Antagonists Under Development for Use in Immuno-Oncology WINNERSH, UNITED KINGDOM--(Healthcare Sales & Marketing Network) - Vernalis plc (LSE: VER) ("Vernalis" or the "Company") today announces Corvus Pharmaceuticals, Inc. ...
Biopharmaceuticals, Licensing
Vernalis, Corvus, adenosine antagonist, adenosine

Audentes Therapeutics Appoints Scott W. Morrison to Board of Directors

周二, 01/05/2016 - 14:46
SAN FRANCISCO--(Healthcare Sales & Marketing Network)--Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced the appointmen...
Biopharmaceuticals, Personnel
Audentes Therapeutics, gene therapy

Rhythm and Camurus Announce License Agreement for Extended Release FluidCrystal Setmelanotide

周二, 01/05/2016 - 14:42
BOSTON and LUND, Sweden, Jan. 5, 2016 -- (Healthcare Sales & Marketing Network) -- Rhythm and Camurus announced today a license agreement for the use of Camurus' drug delivery technology, FluidCrystal®, to formulate setmelanotide (RM-493), Rhythm's no...
Biopharmaceuticals, Drug Delivery, Licensing
Rhythm, Camurus, FluidCrystal, Setmelanotide, obesity

Glenn P. Sblendorio to Join Ophthotech as Executive Vice President, Chief Operating Officer and Chief Financial Officer

周二, 01/05/2016 - 14:39
Michael G. Atieh to Retire as Executive Vice President and Chief Financial and Business Officer; Transition Expected at End of First Quarter 2016 NEW YORK--(Healthcare Sales & Marketing Network)--Ophthotech Corporation (OPHT) today announced that Glenn ...
Biopharmaceuticals, Ophthalmology, Personnel
Ophthotech, Fovista, wet AMD, Zimura, dry AMD

Editas Medicine Expands Leadership Team with Key Organizational Appointments

周二, 01/05/2016 - 14:36
Timothy D. Hunt Joins Editas Medicine as Senior Vice President of Corporate Affairs, Haiyan Jiang, Ph.D., as Vice President of Preclinical Science CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Editas Medicine, a leading genome editing compan...
Biopharmaceuticals, Personnel
Editas Medicine, genomic medicine

Ionis Pharmaceuticals Receives Orphan Drug Designation from the US FDA for IONIS-HTT Rx for the Treatment of Patients with Huntington's Disease

周二, 01/05/2016 - 14:31
First therapy designed to directly target the cause of disease CARLSBAD, Calif., Jan. 5, 2016 -- (Healthcare Sales & Marketing Network) -- Ionis Pharmaceuticals, Inc. (IONS) today announced that the U.S. Food and Drug Administration has granted Orphan ...
Biopharmaceuticals, Neurology, FDA
Ionis Pharmaceuticals, antisense, IONIS-HTTRx, Huntington's Disease

United-Guardian Receives FDA Approval to Market New Single-Dose Form of Renacidin(R)

周一, 01/04/2016 - 23:57
HAUPPAUGE, N.Y., Jan. 04, 2016 -- (Healthcare Sales & Marketing Network) -- United-Guardian, Inc. (UG) announced today that it has received FDA approval of its Supplemental New Drug Application to market a new single-dose form of Renacidin® (Citric Aci...
Biopharmaceuticals, FDA
United-Guardian, Renacidin

Padlock Therapeutics Creates West Coast Operations Appointing Scientific Co-founder Kerri Mowen, Ph.D., as Director of Biology Based in San Diego

周一, 01/04/2016 - 23:55
Scientific Co-Founder Will Lead Operations in San Diego; Company Increases Cambridge Presence with New Corporate Offices and Laboratories CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Padlock Therapeutics, a biotechnology company dedicated t...
Biopharmaceuticals, Personnel
Padlock Therapeutics, protein-arginine deiminase, autoimmune

Ardelyx Strengthens Executive Leadership Team with the Appointment of Paul Korner, MD, MBA, as Executive Vice President and Chief Medical Officer

周一, 01/04/2016 - 13:14
FREMONT, Calif., Jan. 4, 2016 -- (Healthcare Sales & Marketing Network) -- Ardelyx, Inc. (ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Paul Korner, MD, MBA, joined the Compan...
Biopharmaceuticals, Gastroenterology, Personnel
Ardelyx, tenapanor, irritable bowel syndrome

PLx Pharma Appoints Natasha Giordano as CEO

周一, 01/04/2016 - 13:11
Experienced Pharmaceutical Executive Brings 25 Years of Leadership and Marketing Expertise HOUSTON--(Healthcare Sales & Marketing Network)--PLx Pharma Inc. (PLx), a privately-held, late-stage specialty pharmaceutical company initially focused on develop...
Biopharmaceuticals, Drug Delivery, Personnel
PLx Pharma, PLxGuard

GORE BIO-A Tissue Reinforcement Proven as Effective as a Biologic Mesh for Complex Ventral Hernia Repair

周一, 01/04/2016 - 13:06
Final study results of bioabsorbable mesh shows significant improvement in patient quality of life while offering cost-savings to hospitals and payors FLAGSTAFF, Ariz.--(Healthcare Sales & Marketing Network)-- W. L. Gore & Associates, Inc. (Gore) today ...
Devices, Surgery
W. L. Gore, Tissue Reinforcement, biosynthetic mesh, hernia repair

Scholar Rock Announces $36 Million Series B Financing

周一, 01/04/2016 - 13:01
Proceeds to finance further expansion of novel supracellular activation platform and advancement of multiple therapeutics into development CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Scholar Rock, a biotechnology company focused on discove...
Biopharmaceuticals, Venture Capital
Scholar Rock, supracellular activation

Conventus Orthopaedics, Inc. Appoints New Board Member

周一, 01/04/2016 - 12:56
Scott Flora Brings More Than 35 Years of Medical Device Industry Experience MINNEAPOLIS, MN--(Healthcare Sales & Marketing Network) - Conventus Orthopaedics, a global medical device company dedicated to revolutionizing fracture treatment, today announce...
Devices, Orthopaedic, Personnel
Conventus, Orthopaedics

Lattice Biologics Completes Merger With Blackstone Ventures

周五, 01/01/2016 - 15:26
Biotech Innovator in U.S. and Canada Emerges From Transaction as Lattice Biologics Ltd. SCOTTSDALE, AZ--(Healthcare Sales & Marketing Network) - Lattice Biologics Inc. ("Lattice") is pleased to announce that it has completed its merger with Bl...
Devices, Regenerative Medicine, Mergers & Acquisitions
Lattice Biologics, Blackstone Ventures

Acerus Announces Termination of NATESTO(TM) Agreement with Endo

周四, 12/31/2015 - 14:04
TORONTO--(Healthcare Sales & Marketing Network)--Acerus Pharmaceuticals Corporation (ASP.TO) today announced that the agreement with Endo Ventures Bermuda Limited (an affiliate of Endo International plc) relating to the commercialization of NATESTO™ in the...
Biopharmaceuticals, Distribution
Acerus Pharmaceuticals, Endo International, NATESTO , testosterone replacement

NeuroDerm Announces Start of Patient Enrollment in Phase II Trial of ND0612H for Advanced Parkinson’s Disease

周三, 12/30/2015 - 14:31
First Clinical Efficacy Study Investigating ND0612H Subcutaneously Delivered Liquid Levodopa/Carbidopa for the Treatment of Advanced Parkinson's Disease REHOVOT, Israel, Dec. 30, 2015 -- (Healthcare Sales & Marketing Network) -- NeuroDerm Ltd. (NDRM), a...
Biopharmaceuticals, Neurology
NeuroDerm, ND0612H, Parkinson’s disease, Levodopa, Carbidopa

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong